The hormone therapy tamoxifen can keep cancer from recurring in women with DCIS Tamoxifen following lumpectomy reduced risk of recurrence 44% to 51% Tamoxifen blocks estrogen receptors in cancer cells ...

LCCC 1025: A phase II study evaluating the mTOR inhibitor everolimus with trastuzumab and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Background: Asignificant amount ...

Actress Danielle Fishel shared her breast cancer diagnosis this week, revealing on Monday's episode of her podcast, "Pod Meets World," that she is being treated for ductal carcinoma in situ (DCIS).

Delaying radiation therapy too long after surgery significantly increases the risk of recurrent tumors in women treated for very early, or what is referred to as "stage 0," breast cancer, according to ...

SAN ANTONIO -- Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ipsilateral invasive cancer versus guideline-recommended treatment, the randomized COMET ...

A polygenic risk score (PRS) may help identify women who are at a greater risk of developing a future breast cancer after treatment for in situ breast disease, a retrospective study suggests. The ...

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial Eligibility: Eastern Cooperative Oncology ...

This new study focused on the patient perspective following a diagnosis of ductal carcinoma in situ (DCIS), a noninvasive type of breast cancer also referred to as stage 0 or pre-cancer, as well as ...

Overall, the median time from biopsy to treatment was 35 days, but differed significantly between patients whose diagnosis and treatment occurred at the same center (31 days) versus those who sought a ...